What is the timing of onset and clinical course of premature ovarian insufficiency (POI) in patients with Mulibrey nanism (MUL), a monogenic disorder caused by mutations of the peroxisomal TRIM37 gene?
Introduction
Premature ovarian insufficiency (POI), previously known as premature ovarian failure (POF), is an important cause of female infertility. POI is a complex heterogeneous disorder with a significant genetic contribution (Qin et al., 2015) . POI refers to the development of amenorrhea and increased gonadotropin levels before the age of 40 years. In general, POI develops from either depletion or dysfunction of ovarian follicles (Rebar and Connolly, 1990) , and the depletion can result from either a diminished number of oocytes being formed during embryonic development or an augmented rate of oocyte atresia.
In the majority of POI cases, the etiology remains unknown. Several single genes have been associated with the development of POI, with BMP15, FMR1, NOBOX, NR5A1 and FSHR constituting only a few examples (Qin et al., 2015) . Recently, whole-exome sequencing has emerged as a promising tool for identifying genes involved in POI (Patiño et al., 2017) . POI may develop in an isolated manner in an apparently healthy woman (non-syndromic POI) or as part of a pleiotropic genetic disorder (syndromic POI). Perrault syndrome, harboring mutations of the peroxisomal matrix enzyme HSD17B4, also known as D-bifunctional protein (DBP) or peroxisomal multifunctional enzyme (MFE-2), is until now the only peroxisomal disorder associated with female gonadal insufficiency (Pierce et al., 2010 , Chen et al., 2017 . Syndromic conditions explain only 1% of cases of POI but elucidating the roles that these genes have in reproduction may aid in a better understanding of ovarian biology (Qin et al., 2015) .
MUL is caused by recessive mutations of the TRIM37 gene coding for a peroxisomal membrane protein with ubiquitin E3 ligase activity (Avela et al., 2000; Kallijärvi et al., 2002 Kallijärvi et al., , 2005 Wang et al., 2017) . The pathogenesis underlying the disorder is still unknown but recent findings show that MUL is a new type of peroxisomal biogenesis disorder (PBD) . Worldwide,~150 patients with MUL have been diagnosed, 110 of whom are Finnish. Prenatal-onset growth restriction, distinct craniofacial features, perimyocardial heart disease, severe insulin resistance, as well as a high risk of both benign and malignant tumors are characteristic features (Karlberg et al., 2004a (Karlberg et al., , 2005 (Karlberg et al., , 2009a . Our institution has, since the 1970s, conducted the clinical care and follow-up of Finnish MUL patients, thereby enabling a unique knowledge of this rare patient group.
During the years of clinical follow-up, failure of sexual maturation and infertility in MUL patients became apparent (Karlberg et al., 2004b (Karlberg et al., , 2011 . In this work, we have conducted both a longitudinal study and a cross-sectional study in the national cohort of girls and women with MUL, in order to understand the timing of onset and development of POI in these patients from the postnatal time onwards.
Materials and Methods

Patients
The study cohort included 33 patients, aged 5.1-47.3 years at the end of the study (11 children or adolescents and 22 adults, median age 22.3), who had regular follow-up at the Children's Hospital and the Women's Hospital, University of Helsinki, between years 2004 and 2014 (Fig. 1) . All patients met the diagnostic criteria for MUL and their diagnoses had been confirmed by genetic testing: 32 were homozygous for the Fin-major mutation (c.493-2 A>G), and one was a compound heterozygote for the Finmajor and Fin-minor (c.2212delG) mutations. Of the patients, 27/33 (82%) were born small for gestational age (SGA). Birth length standard deviation score (SDS) was on average −3.2 (range: −6.3 to −0.2), and mean birth weight SDS was −3.0 (range: −4.4 to −0.8). Final adult height was, on average, 140 cm (range: 129-156 cm; median height SDS −4.3).
In six patients (6/33), an early diagnosis allowed observation before the age of 2 years. During growth and pubertal transition, patients were followed up with clinical visits at 6-12-month intervals. The clinical visits included physical examination with evaluation of height, weight and pubertal stage according to Tanner (Tanner, 1962) . The adult patients were followed up at 1-3-year intervals. Medical and menstrual histories, as well as gynecological symptoms were obtained from hospital records and clinical visits. Reproductive hormone analyses including serum gonadotropins, estradiol and anti-Müllerian hormone (AMH, from year 2011) were Figure 1 Study flowchart. All adolescents and women participating in the cross-sectional study had been followed since the beginning of the study. performed once during childhood and once a year from prepuberty (9-11 years) in females without any hormonal substitution. From the six children diagnosed early, blood samples were drawn depending on medical consideration. Sera for later hormonal analyses were, if possible, obtained in conjunction with laboratory analyses and stored at −80°C.
In 2011-2012, a cross-sectional study was conducted in the patients who were pubertal or postpubertal at that time. A total of 19 patients participated (Fig. 1) . The study included gynecological examination with ultrasonography and assessment of serum reproductive hormone concentrations (FSH, LH, estradiol and AMH). The diagnosis of POI was established according to recent ESHRE guidelines (ESHRE Guideline Group on POI et al., 2016) after a documented period of amenorrhea (at least 4 months) without hormonal treatment and FSH levels of at least 25 IU/L in subsequent measurements. Patients were classified as having impending POI when they had oligomenorrhea/amenorrhea without hormonal treatment and AMH levels under the detection limit, implying deteriorated ovarian function.
Ethical approval
The Ethics Committee of Helsinki University Hospital approved the study and the patients and/or their guardians gave an informed consent.
Serum samples and hormone assays
Blood samples were collected before 10 am during the early follicular phase in regularly menstruating patients. In the cross-sectional study, blood samples were drawn after a wash-out period of at least 6 weeks in women receiving hormonal substitution. Serum concentrations of FSH and LH were measured by electrochemiluminescence immunoassays (Elecsys 2010, Roche Diagnostics, Mannheim, Germany). The limit of detection (LOD) was 0.1 IU/L for both assays. For FSH, the inter-assay coefficient of variation (CV) was <5% in the range: 6-178 IU/L and for LH, it was <3% in the range 6-160 IU/L. Serum estradiol was analyzed with an LC-MS-MS system (liquid chromatography coupled with tandem mass spectrometry, API4000, AB Sciex, Concord, Canada); the inter-assay CV was 5.6% at 60 pmol/L and 5.1% at 360 pmol/L. AMH was quantitated by an ELISA assay (AMH Gen II ELISA, Beckman Coulter, Brea, CA, USA); the LOD was 0.1 μg/L and the intra-assay and inter-assay CVs were <6% in the range 4.4-16.5 μg/L. Total CV was <8%. Samples with values below the assay detection limit were assigned the detection limit value. AMH levels <0.1 μg/L were verified by an ELISA kit from Ansh Labs (Webster, TX, USA). Normal reference values for FSH, LH and estradiol were those used in routine at Helsinki University Hospital Laboratory. For prepubertal children, FSH reference values were adapted from Zec et al., 2012 . AMH reference values were adapted from Hagen et al., 2010a, and converted from pmol/L to μg/L by a conversion factor of 7.14. For 
Ultrasonography
Abdominal (n = 6) and/or transvaginal (n = 13) ultrasonography was performed in all patients included in the cross-sectional study (n = 19) and was analyzed by a single observer (A.T.). Uterine size and shape, ovarian size and antral follicle count (AFC) were assessed. All follicles between 2 and 10 mm in both ovaries were regarded as antral follicles. Ovarian volumes were computed using the formula longitudinal diameter × anteroposterior (AP) diameter × transverse diameter × 0.5233 (Porcu et al., 1989) .
Results
Clinical findings
The external genitalia of the MUL infants and children were normal although the vulvar area was often edematous. The onset of puberty, defined as initiation of breast development assessed visually and with breast bud palpation, occurred spontaneously in all patients. Breast development, although beginning appropriately, did not progress adequately. Nipple and areola growth proceeded to a mature stage. However, growth of breast tissue was poor and none of the girls presented enlargement of the breast stroma corresponding to Tanner breast stage B4 or B5.
The development of pubic hair generally appeared prior to breast development and reached Tanner stage PH4-PH5. The pubertal growth acceleration commenced with the onset of breast development but was weak. Median age at menarche was 12.5 years with extensive individual variation (range: 10-17.8 years, mean: 13.1 years). Two adolescents presented with very slow pubertal progress with pubertal arrest. One of the girls had menstrual bleedings induced with cyclic progestin at 16.4 years. The other girl had puberty accelerated with the help of transdermal estrogen treatment, resulting in menarche at 16.3 years.
Of the adolescents and women, 54% (14/26) never attained regular cyclic bleeds. The first signs of ovarian failure appeared on average 1.1 years after menarche with menstrual disturbances ranging from oligomenorrhea to long periods of amenorrhea. Ten years from menarche, only two of the women (2/26, 8%) menstruated regularly. The majority of women (19/26, 73%) were prescribed cyclic progestin treatment, oral contraceptives (OC) or hormone replacement treatment 0-10 years after menarche in order to control bleedings and/or to provide sufficient hormonal levels. Of the women above 18 years of age, 17/21 were living in a settled relationship. None of the women had been pregnant although the majority had hoped to conceive.
Reproductive hormones
Serum FSH levels were markedly elevated in the six infant girls, corresponding to postnatal pituitary activation (Fig. 2) . In contrast, the serum levels of AMH were undetectable or very low (Fig. 2) . The postnatal gonadotropin surge gradually declined, and gonadotropins remained at the low prepubertal level during rest of the childhood, in line with childhood pituitary silence ( Fig. 2 and Table I ). In prepuberty, gonadotropins started to rise to hypergonadotropic levels, and in the group of 15-18-year olds, the FSH level was already elevated (> 12.5 IU/L) in 73% of the adolescents (Table I ). The levels of AMH remained undetectable or low throughout childhood (Table I) . Serum levels of FSH, LH, estradiol and AMH of the 19 adolescents and women participating in the cross-sectional study are presented in Fig. 3 and Table II . Serum FSH levels were elevated in 9/19 of the patients (47%) and LH levels were elevated (>12.6 IU/L) in 9/19 patients (47%). In women over 25 years of age, 86% (6/7) had elevated FSH. Estradiol levels were within the low/normal range. Of the adolescents and women, 89% (17/19) had undetectable AMH levels.
Gynecological evaluation
In the cross-sectional study, no genital anomalies were found but the external genitalia were frequently edematous. The size of the uteri in the patients over 18 years varied from small to normal, and while the uteri were of adult shape, they were typically somewhat narrow (data not shown). The ovaries were small and appeared hypoplastic and dense. In six patients, the mean ovarian volume was measured (1.8 ml, range: 0.3-2.9 ml). None of the patients had normal ovarian morphology under ultrasonography. In two women, ovarian fibrothecomas were found. Of the 17 patients in whom AFC was possible to assess, 8/17 (47%) had no antral follicles, 6/17 (35%) had 1-2 follicles and the remaining three patients had an AFC of 3-6 (Table II ). In addition, four patients presented with follicles of 13-21 mm in diameter, possibly indicating growing follicles.
Development of POI
Of the patients in the cross-sectional study, 15/19 (79%) had signs of ovarian insufficiency. Seven patients (37%) were classified as having POI. The median age for developing POI in this population was 22.0 years (mean: 22.4 years; range: 14-32 years). Eight patients (42%) were classified as having impending POI. In addition to their AMH levels being under the detection limit and oligomenorrhea/amenorrhea, they had FSH levels between 5.7 and 24 IU/L. Four patients (4/ 19) still had principally regular menses but of these, two had AMH levels under the detection limit. Of the seven pubertal or postpubertal women excluded from the cross-sectional study (including the one deceased patient), six had developed POI at a median age of 21.5 years.
Discussion
In this prospective study, we have evaluated the gonadal function, ovarian reserve and development of POI in girls and women with MUL. We conclude that female MUL patients demonstrate incomplete pubertal development and early depletion of the ovarian reserve resulting in POI and infertility. Thus, MUL should be added to the list of syndromes associated with POI and, correspondingly, TRIM37 should be added to the growing list of genes associated with POI. In addition, TRIM37 is one of the first known peroxisomal genes associated with female gonadal failure and infertility.
Infant MUL girls presented with a strong postnatal pituitary activation (minipuberty). This is in line with previous findings showing that postnatal FSH levels are higher in SGA infants compared to infants born appropriate for gestational age (Ibáñez et al., 2002a) . In healthy girls, the postnatal gonadotropin surge stimulates ovarian folliculogenesis and serum AMH levels increase soon after birth, peaking a few months postnatally (Kuiri-Hänninen et al., 2014) . AMH levels increase again from 4-8 years of age but are then stable until early adulthood (Hagen et al., 2010a) . In our patients, however, AMH levels were undetectable or very low throughout childhood. In all six young girls followed up from infancy, the AMH concentration was below the detection limit of the assay at least at one measuring point. Whether this indicates a compromised pre-or postnatal folliculogenesis or early follicular loss remains to be established. During mid-childhood, gonadotropins were normal or slightly elevated but started to rise to hypergonadotropic levels in prepuberty. A similar amplified biphasic age pattern of gonadotropins can also be seen for example in girls with Turner syndrome (TS) (Hagen et al., 2010b) . Despite the low AMH levels, puberty occurred spontaneously in all girls. Thus, although the number of follicles is highly reduced already in MUL girls, it still appears to be sufficient to induce the partial development of secondary sexual characteristics and to allow uterine growth.
The vast majority of the patients in our cohort were born SGA. Conflicting data exist about the relationship between being born SGA and gonadal or reproductive function (de Bruin et al., 1998; Ibáñez et al., 2002b) . However, recent studies indicate that the ovarian follicle pool is not compromised by fetal growth restriction alone as evidenced by similar AMH levels between prepubertal short SGA and healthy control girls (Meas et al., 2010) . Therefore the results of diminished ovarian reserve in MUL are probably not confounded by being born SGA.
The serum level of AMH strongly correlates with the number of growing follicles . Only two MUL women had measurable AMH levels (23 and 26 years of age, respectively) and these were also among the patients with the most regular menstrual cycles. Thus, in MUL, AMH is the earliest marker of reduced ovarian function. In recent years, AMH has emerged as a recognized marker of Aksglaede et al., 2009 and Lie Fong et al., 2012. ovarian reserve and a putative marker for ovarian ageing (de Vet et al., 2002; Broer et al., 2014) . In patients with TS, the AMH level is a good predictor of ongoing ovarian function or POI (Hagen et al., 2010a) . We show that also in MUL, AMH seems to be a reliable marker of gonadal function as AMH levels were consistent with the morphological findings of the ovaries in ultrasonography.
The majority (79%) of the adolescents and women participating in the cross-sectional study were classified as having either POI or impending POI. In POI, the decline in ovarian function usually progresses intermittently (De Vos et al., 2010) and this was also noted in our patients. Of the women over 25 years, 86% had elevated FSH, corresponding well with the mean age of 22.4 years for developing POI in this population.
During our follow-up study none of the MUL women were pregnant. Some of the patients had a few follicles in their ovaries but we have not performed ovarian stimulation of MUL women at our institution due to low AFC and AMH. The hemodynamic changes associated with pregnancy are also a subject of concern, potentially having adverse effects on the MUL heart disease. If cardiovascular and general health permit, oocyte stimulation may potentially be considered in young MUL patients with follicles. POI denotes loss of the ovarian follicle pool, therefore interventions aiming at fertility preservation (oocyte or ovarian tissue cryopreservation) represent a challenge, the timing of which should be carefully planned (ESHRE Guideline Group on POI et al., 2016) . In TS, for instance, the follicle pool is already seriously reduced in prepuberty, which is considered the major limiting factor for fertility preservation (Grynberg et al., 2016) . The situation in MUL resembles that of Turner patients. Oocyte donation is still considered the most effective treatment of infertility associated with POI (ESHRE Guideline Group on POI et al., 2016) and could also be considered in carefully selected MUL women.
The Finnish MUL patients genotypically constitute a homogenous group with >95% having a homozygote mutation of Fin-major. It is possible, that different TRIM37 mutations lead to different hypogonadal phenotypes. To date, no genotype-phenotype correlation has been demonstrated in MUL (Hämäläinen et al., 2004) . In our earlier study from 2004, one female was a compound heterozygote and had ovaries with normal morphology as assessed by ultrasonography at the age of 29.5 years (Karlberg et al., 2004b) . This patient, who was not a part of this cross-sectional study due to her high age, later developed POI (at the age of 34 years) similarly to the females with homozygous mutations, implying that POI is not only limited to Fin-major mutations.
The recently described Trim37 knock-out mouse model largely recapitulates the reproductive phenotype seen in MUL (Kettunen et al., 2016) . In contrast to the human MUL patients, however, male mice were not able to reproduce at all whereas female mice were fertile for a short time after puberty. Trim37 −/− mice demonstrated early germ cell degeneration with total aplasia at the age of 1 month in male mice and 6 months in female mice (Kettunen et al., 2016) . This also supports a role for the TRIM37 protein in ovarian development and function. TRIM37 prevents centriole reduplication events in human cells implying an important role in chromosome segregation and genome stability (Balestra et al., 2013) . The exact developmental timing and the underlying cause of POI in MUL remain unknown. According to this study, the follicular pool is already strongly reduced at birth, supported by the fact that AMH levels were low or undetectable in the youngest patients in our cohort. Recently, Wang et al. (2017) showed that dysfunction of TRIM37 induces apoptosis, which supports the hypothesis of an enhanced rate of follicular atresia leading to POI in MUL. The study of monogenic disorders associated with POI, such as MUL, may ultimately provide insight into the development and function of normal ovaries as well as the mechanisms of ovarian insufficiency.
